Applied DNA Schedules Fiscal 2020 Second Quarter Financial Results Conference Call for Thursday, May 14, 2020 at 4:30 PM ET
May 07 2020 - 7:00AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it
plans to release financial results for its fiscal 2020 second
quarter ended March 31, 2020 after market close on Thursday, May
14, 2020. In conjunction with the release, the Company has
scheduled a conference call at 4:30 p.m. Eastern Time that will
also be broadcast live over the Internet.
What:
Applied DNA’s Fiscal 2020 Second Quarter
Financial Results Conference Call
When:
Thursday, May 14, 2020, at 4:30 p.m.
Eastern Time
Where:
Via phone by dialing +1-844-887-9402 or
+1-412-317-6798 and ask to join the Applied DNA call; via
webcast.
A telephonic replay of the conference call will be available for
one week beginning one hour after the end of the live conference
call. Replay can be accessed by calling 1-877-344-7529 or
+1-412-317-0088 with the passcode 10141899. The webcast will be
archived within the ‘Events and Presentations’ portion of the
‘Investors’ page to the company’s website.
About Applied DNA Sciences, Inc.
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
LinearDNA™ is a trademark of Applied DNA Sciences, Inc.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN’, and its publicly-traded warrants are listed on OTC
under ticker symbol ‘APPDW’.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to the possibility
of a failure to make timely payment on its outstanding secured
convertible notes and resulting enforcement by noteholders of
remedies on collateral which includes substantially all of Applied
DNA’s assets, its history of net losses, limited financial
resources, limited market acceptance, the fact that there has never
been a commercial drug product utilizing PCR-produced DNA
technology approved for therapeutic use, the uncertainties inherent
in research and development, future clinical data and analysis,
including whether any of Applied DNA’s or its partners product
candidates will advance further in the preclinical research or
clinical trial process, including receiving clearance from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at
all, they will receive final approval from the U.S. FDA or
equivalent foreign regulatory agencies, and various other factors
detailed from time to time in Applied DNA’s SEC reports and
filings, including our Annual Report on Form 10-K filed on December
12, 2019 and our subsequent quarterly report on Form 10-Q filed on
February 6, 2020, and other reports we file with the SEC, which are
available at www.sec.gov. Applied DNA undertakes no obligation to
update publicly any forward-looking statements to reflect new
information, events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events, unless otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200507005170/en/
Investor contact: Sanjay M. Hurry, LHA Investor
Relations, 212-838-3777, shurry@lhai.com Web: www.adnas.com
Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2024 to May 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From May 2023 to May 2024